<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125110</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01420-45</org_study_id>
    <nct_id>NCT02125110</nct_id>
  </id_info>
  <brief_title>PERINE : Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain : an MRI Study</brief_title>
  <acronym>PERINE</acronym>
  <official_title>Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain: an MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims at evaluating the consequences of prenatal exposure to neurotoxicants
      (solvents, organophosphate pesticides) on the developing brain, in children aged from 10 to
      12 years.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Measurement of the brain activity and its functionality</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the fractional anisotropy of the regions of interest on MRI :
- with DTI (Diffusion Tensor Imaging) : DTI can be used to generate quantitative maps of the scalar (anisotropy, based on measurements of FA and mean diffusivity (MD)) or tensor (diffusivity expressed in the form of a 3x3 matrix) type. An intergroup analysis will be carried out to identify regions with FA and MD values different between exposed and non-exposed subjects. Tractography of the fibre bundles in the white matter could also be carried out, based on regions of interest extracted, for example, from high resolution morphometry or functional activation maps. The connectivity between these different regions may also be studied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the brain activity and its functionality</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the cerebral blood flow and the activation of the regions of interest on MRI with :
BOLD-fMRI (Blood Oxygen Level Dependent) : detection of the voxels activated, for each child, during the tasks (motor inhibition (Go / No-Go), attention (Posner's task) and working memory (N-back)) and comparison of levels of brain activation between exposure groups
ASL (Arterial Spin Labeling) : quantitative value for cerebral blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of neuropsychological tests</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between the results of neuropsychological tests (subtests of the NEPSY (developmental NEuroPSYchological assessment) and the WISC-IV (Wechsler Intelligence Scale for Children version IV) tests that will evaluate motor inhibition, attention, working memory and graphomotor capacities) and MRI measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Effects of Neurotoxicants on the Brain</condition>
  <arm_group>
    <arm_group_label>study group (cohort PELAGIE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 children included in the cohort PELAGIE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pilot group (no cohort PELAGIE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 children not included in the PELAGIE cohort to optimise MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>study group (cohort PELAGIE)</arm_group_label>
    <arm_group_label>pilot group (no cohort PELAGIE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological assessment</intervention_name>
    <arm_group_label>study group (cohort PELAGIE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children included in the cohort PELAGIE

          -  Children participated in the study PEPSY

          -  Age between 10 and 12 years (pilot study)

        Exclusion Criteria:

          -  Maternal smoking and or alcohol consumption during pregnancy (study group)

          -  Children with a health event affecting neurodevelopment

          -  Children treated with methylphenidate, psychotropic or anti-epileptics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabienne FP Pelé</last_name>
    <phone>33-2-9928-9302</phone>
    <email>fabienne.pele@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabienne FP Pelé</last_name>
    </contact>
    <investigator>
      <last_name>Fabienne FP Pelé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurotoxicants</keyword>
  <keyword>MRI</keyword>
  <keyword>developing brain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
